Innovator companies want the FDA to adopt separate names for biosimilars. Manufacturing changes aren’t drastic enough to make it necessary, experts argued at an FTC workshop.
Sandoz wades into Humira biosimilars
December 19, 2013
7:52 pm
The generics maker says an adalimumab biosimilar would anchor its immunology portfolio.
Lantus-like rivals can expect a wary reception from endocrinologists, even if these biosimilars reach market, researchers predict.
Calif. governor vetoes biosimilars bill
October 15, 2013
5:06 pm
The governor says it is too early to legislate on drugs the FDA is still deliberating over.
Business briefs: Biogen, Celgene, J&J, plus Obamacare TV push
September 9, 2013
5:16 pm
Biogen extend Isis relationship for six years and $100M; HHS readies healthcare reform TV push; Medivir ends hep. B clinical trial; FDA approves Celgene cancer drug; Baxter seeks Enbrel biosimilar
Business briefs: Biosimilars, Johnson & Johnson, Consumer Reports
August 29, 2013
5:57 pm
FDA is concerned state biosimilar legislation could make consumers uneasy about the category, J&J hands $75 million milestone payment for ibrutinib, Consumer Reports gets into drug apps
Business briefs: Medtronic, Novo Nordisk, plus OIG’s latest probe
August 12, 2013
6:11 pm
Medtronic buys up Cardiocom, Novo will file liraglutide to battle obesity, HHS navigates cutback and looks into anti-psychotic prescription rates, Amgen’s Neulasta to compete against Teva’s Lonquex.
Business briefs: Glaxo, Teva, Johnson & Johnson
July 25, 2013
6:29 pm
Glaxo shakes up China division, Teva and Lonza break up their biosimilars pact, and FDA’s breakthrough designation speeds review but not international and payer uptake.
GA101 looks more like a franchise-extender for Roche